Complex Addiction-Developmental Disorder (CADD): A Proposal for a Distinct Psychiatric Entity for Substance-Related Disorders with Onset During Pre- and Adolescent Development

1. Background and Problem Statement

Substance use disorders are among the most prevalent and consequential psychiatric conditions worldwide, and recent reviews suggest that current treatment frameworks remain structurally inadequate to address their full scope [1]. ICD-11 and DSM-5-TR both classify substance-related disorders under a single framework regardless of the age at which they began. This seems like an obvious problem once you consider what neuroscience tells us about adolescent brain development.

The onset of repeated, pathological substance use in childhood or adolescence falls squarely within a period when fundamental neural networks are still being built—including the mesolimbic reward system, prefrontal impulse regulation, and the circuits underlying attachment and identity [1,2,15]. Psychoactive substances introduced during this window do not simply damage an existing system; they alter the construction process itself. The epidemiological data are consistent with this picture: earlier age at first use predicts faster transition to SUD and markedly worse long-term outcomes across multiple substances and populations [6,7,11].

This paper proposes, drawing on the established construct of C-PTSD [3,4], the nosological category of Complex Addiction-Developmental Disorder (CADD). CADD is not conceived as a subtype or early-onset variant of SUD. It is a structurally distinct clinical entity requiring its own diagnostic criteria and therapeutic approach. The recent inclusion of C-PTSD in ICD-11 [4,10] is directly relevant here—it shows that the field has already accepted the principle that developmental context changes the nature of a disorder, not just its severity. The logical next step is to apply that principle to substance-related conditions.

2. Conceptual Basis: The Analogy to C-PTSD

The PTSD/C-PTSD distinction is the clearest available model for what this paper is arguing. Repeated trauma exposure during neuroplastic developmental phases does not produce a more severe version of PTSD—it produces a different disorder, one characterised by pervasive disturbances of identity, affect regulation, and interpersonal functioning that PTSD criteria simply do not capture [3]. This has now been confirmed by a substantial body of clinical and neurobiological research supporting the ICD-11 operationalisation of C-PTSD as a distinct entity [4].

The parallel for substance use is direct. Repeated substance use during adolescence does not produce a younger or more severe version of adult addiction. The brain is not integrating a psychoactive substance into a pre-existing regulatory framework—it is building that framework, partially, around the substance. The result is something structurally different from what happens when an adult becomes addicted. Recent work in developmental neuroscience confirms that early pharmacological or environmental perturbations produce circuit-level changes that persist into adulthood and resist standard intervention [13,15].

The central claim of this paper can be stated simply: CADD is to SUD what C-PTSD is to PTSD.

3. Neurobiological Basis

Adolescence is not just a period of psychological change—it is a period of major structural and functional brain reorganisation. The prefrontal cortex and its connections to limbic structures are still maturing; the mesolimbic dopaminergic system is differentiating; the neural architecture underlying attachment and identity formation—mediated through GABAergic, glutamatergic, and serotonergic systems—is being laid down [1,15]. This is a window of exceptional neuroplasticity, and one of unusual vulnerability.

The substance classes most relevant to CADD—GABAergic compounds (alcohol, benzodiazepines) and NMDA antagonists (ketamine)—act directly on the systems undergoing this reorganisation. Their effects are not limited to acute reward signaling; they interfere with the differentiation of emotional regulatory circuitry, the development of self-perception, and the formation of attachment representations. Dopaminergic modulation of incentive motivation during this period is particularly consequential: reward-learning patterns consolidated under substance influence may become structurally embedded in the self-regulatory system in ways that would not occur in a mature brain [8].

The pathology that results is therefore not best understood as damage to an existing system. It is better characterised as a pharmacologically induced neurodivergence: capacities for self-regulation and identity organisation that would otherwise develop substance-free instead crystallise around the substance as a necessary input. The parallel from adversity research is instructive—early environmental perturbations, including pharmacological ones, produce stable alterations in stress-response circuitry and self-regulatory architecture that outlast the original exposure [13]. In individuals with genetic vulnerability to bipolar or psychotic spectrum disorders, this dynamic carries an additional risk: substance-induced activation of these systems during sensitive periods may trigger secondary psychiatric conditions that then become self-sustaining [1,15].

4. Clinical Core Features and Differentiation from Adult SUD

4.1. Substance as Attachment Object and Self-Anchor

The most fundamental clinical difference between CADD and adult SUD lies in what the substance means to the person—functionally and subjectively. Adult addiction is typically driven by hedonic reward-seeking, avoidance of withdrawal, or self-medication of a pre-existing disorder. In CADD, the substance has taken on a different kind of role altogether.

Repeated use during active identity and attachment development causes the substance to become structurally incorporated into the self-concept. It is not experienced as an external resource but as a constitutive part of the person’s own regulatory and self-governing capacity—something closer to an internal anchor than a drug. Clinically, the relationship to the substance shows features we normally associate with attachment representations: the substance functions as a refuge, a source of self-coherence, or an identity-stabilising reference point [5]. This is not metaphorical. Developmental attachment research shows that early relational experiences shape internal working models of self and other [12]; CADD proposes that pharmacological exposure during those same developmental phases can produce structurally analogous effects, with the substance occupying the kind of organising position normally held by a caregiving figure.

This explains why abstinence in CADD is phenomenologically different from withdrawal in adult SUD. What is being lost is not just a substance but a self-anchor. Acute CADD crises can involve intense fear of dissolution, ego-disintegration experiences, dissociation, and autonomic hyperactivation—a presentation closer to attachment rupture than to classical craving.

4.2. Substance Preference and Addiction Profile

CADD-affected individuals tend to show a characteristic preference for substances that profoundly modulate consciousness and subjective experience—particularly GABAergic substances and NMDA antagonists. Highly hedonic, dopaminergically active substances may actually carry lower addictive pull in a CADD profile, because the primary function being served is not pleasure but the maintenance of substance-bound self-regulation. Standard dependence criteria—centred on tolerance, withdrawal, and hedonic craving—will therefore systematically fail to capture what is clinically central in CADD [1].

4.3. Comorbidities and Overlaps

CADD overlaps with several other diagnostic categories without being reducible to any of them. C-PTSD and attachment disorders share the mechanism of developmentally conditioned structural deformation [3,4]. Early-onset eating disorders present an analogous architecture, where an externally available module comes to serve identity-stabilising regulatory functions. BPD is the closest overlap diagnostically—identity diffusion, affect dysregulation, and unstable self-representation are central to both—and contemporary BPD frameworks increasingly locate its origins in developmental disruption [14]. ADHD and autism spectrum conditions increase CADD vulnerability, as substance-based coping tends to emerge precisely where alternative regulatory capacities are limited [1].

The secondary consequences are severe: executive dysfunction, substance-related trauma and subsequent PTSD, paradoxical substance reactions, high chronification rates, physical morbidity, and elevated mortality through overdose and suicide. Longitudinal evidence indicates that adolescent-onset SUD severity is among the strongest available predictors of adult psychiatric impairment and functional disability [2].

5. Therapeutic Implications

The reclassification of CADD has direct and non-trivial consequences for treatment. Abstinence as a primary therapeutic goal is not simply insufficient in CADD—it can be actively harmful. Abrupt withdrawal does not leave behind a sober self waiting to emerge; it can collapse the regulatory architecture that the substance has been holding together, producing a regressive, functionally disorganised state, particularly in cases where no stable ego-structure had formed prior to substance use.

The primary therapeutic goal must therefore be identity integration: the slow reconstruction of a self-concept in which the functions previously served by the substance are gradually taken over by substance-independent capacities. This requires clinical competency in developmental psychopathology and trauma-focused approaches. The closest existing models are trauma- and identity-focused treatments developed for C-PTSD and BPD [4,14]—not standard addiction protocols, which are built on assumptions about the person-substance relationship that do not hold in CADD.

Repeated relapse under abstinence-focused treatment, in CADD, should not be read as patient resistance or failure of motivation. It is a predictable consequence of applying the wrong therapeutic model. Recognising this matters both clinically and for how treatment outcomes are designed and interpreted in research.

6. Nosological Implications and Outlook

Current classification systems make no age-dependent distinctions within substance-related disorders. The precedent for such distinctions already exists: Foetal Alcohol Syndrome is recognised precisely because substance exposure during a critical developmental phase produces qualitatively different pathology than equivalent exposure in a mature organism. The same logic applied to C-PTSD—developmental context does not merely moderate a disorder, it changes its nature—and that argument succeeded in producing a new ICD-11 category [4,10].

A parallel revision is warranted for SUD. A spectrum model accounting for age at onset, degree of neurological maturity at the time of first repeated exposure, and the extent of developmental influence would provide a more accurate nosological map of substance-related pathology. The epidemiological evidence already shows that adolescent-onset SUD carries substantially worse long-term trajectories than adult-onset SUD [2,11]; the missing piece is a framework that explains this difference at the level of psychopathological structure rather than treating it as a mere severity gradient. CADD is a proposal for that framework.

7. Original Contribution: Demarcation from Existing Literature

7.1. Existing Research Strands

Several building blocks of the CADD concept are already present in the literature, even if no one has assembled them in this way. The neurobiological vulnerability of the adolescent brain to psychoactive substances is well established [1,15]. The relationship between early substance use and later addiction risk is robustly supported [6,7,11]. Flores [5,9] developed the most sustained existing account of addiction as an attachment disorder, arguing that dependency functions as a repair attempt in the context of early attachment failure. This is genuinely close to the CADD framework—but Flores is primarily concerned with adult populations, and the attachment component in his account is an aetiological antecedent, a wound that precedes and motivates the addiction. CADD proposes something different: that developmental exposure to substances can itself produce attachment-like and identity-constitutive effects, regardless of prior attachment history. The C-PTSD literature [3,4] provides the methodological precedent for this kind of nosological move. Adversity neuroscience [13] and developmental attachment research [12] supply mechanistic and conceptual support.

7.2. Original Contributions of the CADD Concept

Four specific contributions distinguish CADD from what already exists in the literature.

(1) Nosological transfer of the C-PTSD principle to substance-related disorders. The elevated risk of early substance use is well documented [6,7,11], and C-PTSD’s validity as a developmentally conditioned distinct entity is established [4]. What has not been done is to formally apply the C-PTSD model to substance-related pathology. The claim that CADD constitutes a structurally distinct entity—not a subtype or variant of SUD—has no direct precedent in the literature.

(2) Substance as constitutive self-component. Flores [5,9] treats the substance as a replacement for missing external attachment objects. CADD postulates something more radical: that repeated developmentally-phased exposure causes the substance to become an internal, constitutive component of self-structure. The distinction matters therapeutically—you cannot treat the removal of a constitutive self-component the same way you treat the loss of an external comfort object. This claim extends beyond attachment theory [12] and adversity neuroscience [13] while drawing on both.

(3) Crisis dynamics beyond classical craving. The description of acute CADD crises as identity-rupture events—involving ego dissolution, dissociation, and attachment-like loss rather than hedonic deprivation—does not appear in the existing literature with this specificity or framing. Comprehensive SUD reviews [1] do not address this phenomenological dimension in developmental presentations.

(4) Therapeutic framework model. The implication that abstinence-first treatment may be not only ineffective but counterproductive in CADD, and that identity integration is the appropriate primary goal, is a direct theoretical consequence of the CADD model. It has no equivalent in existing SUD treatment frameworks. The closest analogues are identity-focused trauma and personality disorder treatments [4,14], but these were not developed with substance-constituted self-structures in mind.

This is not primarily a synthesis of existing findings. It is a proposal for a new nosological framework, formulated from the intersection of developmental psychopathology, attachment theory, and clinical observation, and intended as a hypothesis for empirical examination.

8. Limitations and Research Needs

This is a conceptual paper, not an empirical study. CADD has not been validated through clinical trials, epidemiological research, or neurobiological measurement. The following questions define the primary empirical agenda.

(i) Can CADD-specific features—substance-as-self-component, identity-bound crisis dynamics—be reliably operationalised and assessed in clinical settings?

(ii) Are there neurobiological markers that distinguish CADD from adult-onset SUD?

(iii) What age and exposure thresholds define the relevant developmental vulnerability window?

(iv) Which therapeutic approaches show efficacy for identity integration as a primary outcome in CADD?

(v) What proportion of individuals currently diagnosed with SUD would meet CADD criteria if these were formalised?

9. Conclusions

This paper argues for the nosological recognition of Complex Addiction-Developmental Disorder (CADD) as an independent psychiatric entity. The argument is straightforward: if developmental context changes the nature of trauma-related pathology—which the ICD-11 recognition of C-PTSD confirms it does [4,10]—then the same logic applies to substance-related pathology. The epidemiological evidence for worse outcomes in adolescent-onset SUD [2,11] already points in this direction; what is missing is a structural account of why. CADD offers that account. Advances in developmental neuroscience [13,15] and the growing evidence base on early-onset SUD trajectories [2,11] make this a tractable empirical question, not just a theoretical one. The development of specific diagnostic criteria, assessment tools, and treatment protocols is the next step. This paper is meant to start that conversation.